Allozyne to Go Public via Reverse Merger with Poniard Pharmaceuticals
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 7 (Table of Contents)
Published: 4 Jul-2011
DOI: 10.3833/pdr.v2011.i7.1488 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to access the public markets, Allozyne, which specialises in conjugated protein therapeutics, has entered into a reverse merger agreement with cash-strapped Poniard Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018